Literature DB >> 14627907

Membrane pore size impacts performance of a xenogeneic bioartificial liver.

Takakazu Matsushita1, Bruce Amiot, Joseph Hardin, Jeffrey L Platt, Scott L Nyberg.   

Abstract

BACKGROUND: We have developed a novel bioartificial liver (BAL) composed of porcine hepatocyte spheroids in a reservoir design. A semipermeable membrane is used to protect the spheroids from immune-mediated damage. This study was designed to assess the influence of membrane pore size on performance of the spheroid reservoir BAL.
METHODS: Eight healthy dogs were studied during primary and secondary exposures to the spheroid reservoir BAL using membranes with small (10 nm) or large (200 nm) pores. BAL performance was assessed by multiple functional assays. Spheroids were examined microscopically before and after all BAL treatments. Titers of xenoreactive antibody were monitored until elective death of animals on day 42.
RESULTS: Viability and functional performance of spheroids were significantly greater after all BAL treatments that used membranes with 10-nm versus 200-nm pores. Reduced performance in the 200 nm group was associated with 7.7-fold and 78.0-fold rise in xenoreactive antibody titers after first and second treatments, respectively. Dogs in the 10 nm group remained hemodynamically stable during all BAL treatments, whereas those in the 200 nm group experienced acute hypotension (P<0.001) during second BAL exposures. Microscopic examination of spheroids after BAL treatments indicated that deposition of canine proteins, including complement, was associated with reductions in both viability and functional performance of the BAL.
CONCLUSIONS: The elicited immune response of healthy dogs to a xenogeneic BAL was blocked and BAL performance significantly improved by reducing the permeability of the BAL membrane.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627907     DOI: 10.1097/01.TP.0000080067.79190.3C

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Pivotal preclinical trial of the spheroid reservoir bioartificial liver.

Authors:  Jaime M Glorioso; Shennen A Mao; Brian Rodysill; Taufic Mounajjed; Walter K Kremers; Faysal Elgilani; Raymond D Hickey; Hakon Haugaa; Christopher F Rose; Bruce Amiot; Scott L Nyberg
Journal:  J Hepatol       Date:  2015-03-25       Impact factor: 25.083

2.  Functional evaluation of a new bioartificial liver system in vitro and in vitro.

Authors:  Zhong Chen; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

3.  Pig-to-baboon liver xenoperfusion utilizing GalTKO.hCD46 pigs and glycoprotein Ib blockade.

Authors:  John C LaMattina; Lars Burdorf; Tianshu Zhang; Elana Rybak; Xiangfei Cheng; Raghava Munivenkatappa; Isabelle I Salles; Katleen Broos; Evelyn Sievert; Brian McCormick; Marc Decarlo; David Ayares; Hans Deckmyn; Agnes M Azimzadeh; Richard N Pierson; Rolf N Barth
Journal:  Xenotransplantation       Date:  2014-03-17       Impact factor: 3.907

4.  Optimization of mass transfer for toxin removal and immunoprotection of hepatocytes in a bioartificial liver.

Authors:  Geir I Nedredal; Bruce P Amiot; Peter Nyberg; Jennifer Luebke-Wheeler; Joseph B Lillegard; Travis J McKenzie; Scott L Nyberg
Journal:  Biotechnol Bioeng       Date:  2009-12-01       Impact factor: 4.530

5.  Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure.

Authors:  Yi Li; Qiong Wu; Yujia Wang; Chengxin Weng; Yuting He; Mengyu Gao; Guang Yang; Li Li; Fei Chen; Yujun Shi; Bruce P Amiot; Scott L Nyberg; Ji Bao; Hong Bu
Journal:  Theranostics       Date:  2018-11-09       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.